Novartis Ag

Fraser Glickman

Gebhard Thoma

Markus Streiff

Hans-Günter Zerwes

Ian Lewis

Rolf Baenteli

Jiri Kovarik

The invention relates to isothiourea derivatives of formula I: wherein Ris a residue of one of the following structures: where the variables are as defined in the claims of the invention, as well as processes for production of these compounds.

Isothiourea derivatives of imadazo[2,1-b]Thiazoles and 5,6-dihydro derivatives thereof useful as CXCR4 chemokine receptor inhibitors

Disclosed are ergoline derivatives, Formula (I), wherein either each of Rand R, independently, is H; optionally Rand/or R-substituted-phenyl or -phenyl-Calkyl; optionally Rand/or R-substituted-heteroaryl or -heteroaryl-Calkyl; optionally Rand/or R-substituted heteroaryl N-oxide; optionally R-substituted C-Calkyl; optionally R-substituted C-Calkenyl, optionally R-substituted C-Calkynyl; optionally R-substituted C-Ccycloalkyl, or optionally R-substituted C-Ccycloalkenyl; or Rand Rform together with the nitrogen atom to which they are attached an optionally R-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; Ris H; OR; CHRR; (CH)NRR; CH&#x2014;CH&#x2014;OR; CH&#x2014;CO&#x2014;NRR; or CO&#x2014;CHRR; Ris F; Cl; Br; I; OR; NRRor has one of the significances given for R; and Rhas one of the significances given for R, in free form or in salt form for preventing or treating disorders or diseases mediated by interactions between chemokine receptors and their ligands. 

Ergoline derivatives

Growing community of inventors

Basel, Switzerland

Fraser Glickman